Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Natasha on +44 1494 818 053 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Natasha Wilson
Executive Recruiter
+44 1494 818 053

I could not speak more highly of Zenopa and my Account Manager. From the word go I found them to be fully professional and helpful keeping me updated all the way through the recruitment process and al...
Phil, 2013

Bristol-Myers Squibb licenses cancer drug from Innate Pharma

7 July 2011 00:00 in Pharmaceutical Company Product News

Bristol-Myers Squibb has announced a new global licensing deal that will allow it to develop and commercialise a new cancer compound created by Innate Pharma.

The agreement pertains to the developmental therapy IPH102, a potential first-in-class biologic that functions by blocking KIR receptors.

It is currently in phase I clinical testing and will continue to be developed by Innate Pharma as an acute myeloid leukaemia therapy until the end of phase II, with Bristol-Myers Squibb to offer its support.

The agreement will see Bristol-Myers Squibb pay an upfront fee of $35 million (21.9 million pounds) for rights to the drug, plus additional payments of up to $430 million based on clinical and commercial milestones.

Francis Cuss, senior vice-president of research at Bristol-Myers Squibb, said: "Bristol-Myers Squibb is dedicated to helping patients prevail over cancer."

Last month, the company partnered with Roche to investigate a new treatment option for metastatic melanoma that combines two of the firms' existing cancer drugs.ADNFCR-8000103-ID-800614330-ADNFCR

Other news stories from 07/07/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd